Isomab is developing an antibody treatment for Peripheral Vascular Disease based on the team’s breakthrough discovery in VEGF-A biology. The treatment has the potential to transform the lives of thousands of people living disease.
Total raised: $9.46M
Investors 1
Funding Rounds 1
| Date | Series | Amount | Investors |
| 20.02.2024 | - | $9.46M | - |
Mentions in press and media 5
| Date | Title | Description | Source |
| 21.02.2024 | IsomAb: A Beacon of Hope for Diabetic Peripheral Arterial Di... | IsomAb, a biopharmaceutical company based in Nottingham, UK, has secured a significant £7.5 million ... | parsers.vc... |
| 20.02.2024 | IsomAb Raises £7.5M in Funding | IsomAb CEO Jackie Turnbull IsomAb, a Nottingham, UK-based biopharmaceutical company, raised £7.5M in... | finsmes.co... |
| 20.02.2024 | IsomAb secures £7.5M for treatment of diabetic peripheral ar... | Today IsomAb — a University of Nottingham spin-out pioneering a new treatment for people with diabet... | tech.eu/20... |
| 14.09.2023 | SCVC's new fund to propel Pre-Seed and Seed stage tech innov... | Early-stage deep tech investor SCVC, has announced the first close of its second fund, with a target... | tech.eu/20... |
| - | IsomAb Closes £7.5 Million To Develop Isoform-Specific Disea... | IsomAb Ltd – a UK-based biotechnology company – announced today the closing of a £7.5 million (appro... | pulse2.com... |